may 17, 2018 -- the fda has approved the first in a new class of migraine drugs that aim to fight painful.

executive director of saen michael budkie made these reports public in a letter addressed to chancellor carol christ on wednesday.

the news highlighted another factor in the chinese threat: regardless of the different regulatory framework, many researchers think the data they report is valid..